In 2005, Medicare began reimbursing for physician-administered drugs at the average manufacturer's sales price plus 6%, to remedy frequent overpayment. Oncologists' response varied geographically, with some states substantially increasing treatment rates.
No takes yet. Share an insight, caveat, or question.
Jacobson et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: